A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs NP 213 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 17 Aug 2017 Planned End Date changed from 30 Jun 2018 to 30 Mar 2018.
- 17 Aug 2017 Planned primary completion date changed from 8 May 2018 to 15 Feb 2018.
- 17 Aug 2017 Status changed from active, no longer recruiting to recruiting.